Agilent Technologies, Inc. (NYSE:A) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue trimmed its holdings in Agilent Technologies, Inc. (NYSE:AFree Report) by 7.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,515 shares of the medical research company’s stock after selling 3,305 shares during the quarter. State of Alaska Department of Revenue’s holdings in Agilent Technologies were worth $5,632,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in Agilent Technologies during the 4th quarter worth approximately $393,291,000. Victory Capital Management Inc. raised its stake in shares of Agilent Technologies by 939.8% during the third quarter. Victory Capital Management Inc. now owns 2,296,512 shares of the medical research company’s stock worth $256,796,000 after purchasing an additional 2,075,649 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Agilent Technologies by 233.7% during the fourth quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock worth $370,552,000 after purchasing an additional 1,867,377 shares during the period. Morgan Stanley grew its position in Agilent Technologies by 79.4% in the 4th quarter. Morgan Stanley now owns 4,145,767 shares of the medical research company’s stock valued at $620,414,000 after buying an additional 1,835,413 shares during the last quarter. Finally, Meritage Group LP acquired a new position in Agilent Technologies in the 3rd quarter valued at $184,437,000.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the sale, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the transaction, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael R. Mcmullen sold 52,297 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $150.00, for a total value of $7,844,550.00. Following the transaction, the chief executive officer now directly owns 253,909 shares in the company, valued at approximately $38,086,350. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,610 shares of company stock valued at $9,220,333.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Oppenheimer lifted their target price on shares of Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Evercore ISI lowered their price objective on Agilent Technologies from $135.00 to $132.00 and set an “in-line” rating on the stock in a report on Wednesday, February 28th. UBS Group increased their target price on Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 19th. Finally, Barclays increased their price objective on Agilent Technologies from $120.00 to $125.00 and gave the stock an “underweight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Agilent Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $138.29.

Read Our Latest Report on A

Agilent Technologies Stock Down 1.3 %

Shares of NYSE A opened at $145.51 on Monday. The firm’s 50-day moving average is $138.57 and its two-hundred day moving average is $126.74. The company has a market capitalization of $42.64 billion, a PE ratio of 34.65, a price-to-earnings-growth ratio of 4.40 and a beta of 1.11. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $151.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04.

Agilent Technologies (NYSE:AGet Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.07. The firm had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company’s quarterly revenue was down 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.37 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.51 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd will be given a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s dividend payout ratio is presently 22.38%.

Agilent Technologies Company Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Read More

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:AFree Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.